根除幽门螺旋杆菌四联疗法中奥美拉唑对比格犬铋吸收的影响  

Effect of omeprazole on absorption of bismuth in quadruple therapy for eradication of Helicobacter pyloriinfection in Beagle dogs

作　　者：郝瑞家[1] 刘有平[1] 梁宁[2] 曾文琴[1] 杨雪明[1] 邸欣[1] 

机构地区：[1]沈阳药科大学药物代谢与药物动力学实验室,辽宁沈阳110016 [2]沈阳药科大学环境化学教研室,辽宁沈阳110016

出　　处：《中国药理学与毒理学杂志》2013年第2期222-226,共5页Chinese Journal of Pharmacology and Toxicology

基　　金：国家科技重大专项资助课题(2009ZX09301-012)~~

摘　　要：目的探讨根除幽门螺旋杆菌四联疗法中奥美拉唑对比格犬体内铋吸收的影响。方法 采用双周期随机交叉试验设计,6只健康比格犬随机分为2组,分别先后po给予胶体果胶铋(B)70 mg+甲硝唑(M)250 mg+四环素(T)250 mg〔BMT〕或奥美拉唑(Ome)40 mg+BMT(70+250+250)mg(Ome+BMT),并于给药前和给药后0.5,1,2,3,4,6,8,10,12和14 h采集血样并预处理,建立火焰原子吸收光谱法并测定比格犬血浆中铋的浓度,并计算其主要药动学参数。结果 成功建立了测定铋血药浓度的火焰原子吸收光谱法,比格犬口服BMT和Ome+BMT后铋的cmax分别为21.7±5.3和(37.5±5.4)μg.L-1,AUC0-t分别为116.3±27.4和(170.1±30.4)μg.h.L-1,tmax分别为3.0±0.6和(3.0±0.6)h,(Ome+BMT)组比BMT组的cmax,AUC0-t显著升高(P<0.05)。结论 根除幽门螺旋杆菌四联疗法中奥美拉唑能显著增加比格犬体内铋的吸收。OBJECTIVE To investigate the effect of omeprazole （Ome） on adsorption of bismuth （B） in quadruple therapy for eradication of Helicobacter pylori infection in Beagle dogs. METHODS A randomized, two-period, cross-over study was conducted in six Beagle dogs. Dogs were po given triple therapy with bismuth （B） 70 mg, metronidazole （M） 250 mg and tetracycline （T） 250 mg （BMT） or Ome 40 mg and BMT（70 ＋250 ＋250） mg（Ome ＋ BMT）. Concentration of B in plasma was determined by flame atomic absorption spectrometry. Pharmacokinetic parameters of B were calculated by DAS 2.0 software and statistical analysis was performed by SPSS 16.0 software. RESULTS The main pharma cokinetic parameters of B after po administratoin of BMT and （Ome ＋ BMT） to Beagle dogs were： Cmax 21.7±5.3 and （37.5 ±5.4）pg.L-1; AUto-t 116.3 ±27.4 and （170.1 ±30.4）ljg.h.L-1; and tmax 3.0 ±0.6 and （3.0 ± 0.6 ） h, respectively. There were statistically significant differences in Cmax and AUCo-t between BMT and Ome ＋ BMT groups （ P 〈 0.05）, but not in tmax CONCLUSION Ome can increase absorption of B in quadruple therapy for eradication of Helicobacter pylori infection in Beagle dogs.

关 键 词：铋 奥美拉唑 原子吸收光谱法 药代动力学 药物相互作用 

分 类 号：R969.1[医药卫生—药理学]